Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Category Primary study
JournalBlood
Year 2019
This article has no abstract
Epistemonikos ID: eae07643b047890db0d5a3f537b8fc3bc554eced
First added on: Feb 11, 2025